Clinical trial
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase…
NCT00003239 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003239 |
|---|---|
| Title | Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | Recombinant Interferon Alfa, Cytarabine, Omacetaxine Mepesuccinate |
| Enrollment | 90 |
| Start date | Mar 1, 1998 |
| Primary completion | Oct 1, 2001 |
| Completion | Oct 1, 2001 |
| First posted | Apr 30, 2004 |
| Last update posted | Jul 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: